Cipla Subsidiary InvaGen Signs Exclusive Deal

InvaGen Pharmaceuticals, a subsidiary of

, has entered into an exclusive agreement with Qilu Pharmaceutical for QL2107, a biosimilar of Keytruda. The agreement marks a strategic development for InvaGen in the biosimilar segment and expands its collaboration with Qilu Pharmaceutical. QL2107 is being positioned as a biosimilar alternative to Keytruda, a widely used oncology therapy. The deal could strengthen InvaGen’s presence in the US biosimilars market and add to its portfolio of complex pharmaceutical products. Investors will track further developments around the agreement, including regulatory progress, commercialization plans and the potential market opportunity for QL2107. The partnership highlights the growing focus of pharmaceutical companies on biosimilars and differentiated therapies.